Original from: genomeweb

Paradigm Health announced last Thursday that it acquired Flatiron Health's clinical research business, establishing a multiyear collaboration between the two companies. 

As part of the deal, the two companies will work to integrate Paradigm's clinical trial support services into Flatiron's OncoEMR electronic medical records platform. The cloud-based platform helps oncologists manage patient care plans, molecular test ordering, billing, and cancer care analytics, among other oncology-related workflows. 

Flatiron has partnered with other companies to integrate their tests into OncoEMR, such as in a similar deal with Natera, which was announced last month. 

Additionally, the deal grants Paradigm access to Flatiron's clinical research solutions and site network, allowing Paradigm to expand its own network along with clinical trial access to new locations and populations. As a result, Paradigm's network will include more than 25 academic medical centers and health systems, as well as access to nearly 100 community oncology practices throughout the US. 

Paradigm anticipates that the deal will also enable it to serve up to 15 of the top 20 biopharmaceutical companies and to streamline post-market approval evidence generation by boosting its capacity to run Phase IV clinical trials embedded into routine care. 

Financial and other terms of the deal were not disclosed. 

"By combining Paradigm Health's AI-powered trial infrastructure with Flatiron's trusted network and support across academic and community oncology sites, we're building a stronger, more connected ecosystem for clinical research — expanding capabilities, accelerating impact, and advancing our shared mission to bring new treatments to patients faster," Flatiron CEO Nathan Hubbard said in a statement.

Source: Paradigm Health Acquires Flatiron Health's Clinical Research Business